During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
|Articles|December 7, 2013
Arming an Anti-CD38 Antibody With Interferon in Myeloma
Author(s)James R. Berenson, MD
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Advertisement
Clinical Pearls
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
- Interferon was used to treat myeloma (maintain remissions) in the 1980s and 1990s
- When paired with interferon, this anti-CD38 agent can enhance tumor-specific activity 10,000x compared with native interferon
- This pairing cured multiple tumors in mice
- It remains unknown if this pairing will have effects on immune and other cells in the human body
<<<
Advertisement
Related to this article
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5